Articles
<![CDATA[PEMENUHAN OBAT COVID-19 DI INSTALASI FARMASI PROVINSI KALIMANTAN SELATAN ]]>
<![CDATA[Laeliyatun Ikrimah]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 1 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (253.955 KB)
|
DOI: 10.36387/jiis.v7i1.826
<![CDATA[Covid-19 pandemic has not ended and reach its peak in July 2021. The handling of this pandemic is carried out with logistical support for treatment as therapy. Antivirus and antibiotic widely used are Oseltamivir75mg, Favipiravir 200mg and Azithromycin500 mg. The purpose of this study was to determine the need and fulfillment of these medicines in 13 cities and health facilities in South Kalimantan. This study uses observational methode with a total sample of the need and fulfillment of these drugs in July 2021 at IFP South Kalimantan which includes IFK in 13 cities and health facilities that serve the handling of COVID-19. The method of analysis used is descriptive analysis with the most usage and the average percentage fulfillment of needs.The result showed that IFP South Kalimantan could meet about 51,35% of the need for Oseltamivir 75mg, 65,71% for Favipiravir 200mg and 38,68% Azithromycin 500mg from the total needs of 13 cities in South Kalimantan. The most commonly used oseltamivir 75mg and azithromycin 500mg were IFK Banjarmasin, Tanah Bumbu and Kotabaru. This indicates that Covid-19 severity was mild in that cities. The most use of favipiravir is Ulin Hospital, Idaman Hospital and Ansari Shaleh Hospital as 3 referral hospitals in the cities of Banjarmasin and Banjarbaru. It is indicate of moderate to severe COVID-19 that requiring hospital treatment. Conclusion of this study are the fullfill of Favipiravir 200mg and Oseltamivir 75mg are more than 50% of IFK need in 13 cities.]]>
<![CDATA[PROFIL PENGGUNAAN OBAT ANTIVIRUS COVID-19 DI RSUD dr. MURJANI-SAMPIT ]]>
<![CDATA[Etik Suryanti]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 1 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
Full PDF (176.664 KB)
|
DOI: 10.36387/jiis.v7i1.842
<![CDATA[Coronavirus Disease 2019 (Covid-19) is an infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2). The World Health Organization (WHO) until now still defines Covid-19 as a global pandemic where this pandemic is the cause of the biggest public health crisis in this century. RSUD dr. Murjani-Sampit uses several antivirals, including Oseltamivir 75 mg, Favipiravir 200 mg, Remdesivir 200 mg. The purpose of this study was to determine the antiviral profile given to covid-19 patients at dr. Murjani-Sampit. This study used a total sample of hospitalized patients who were given COVID-19 antiviral therapy in the period August 2021. This research method used an observational research design with retrospective sampling. Data collection techniques based on observation of patient prescription data recorded in the pharmacy installation management information system of RSUD dr. Murjani-Sampit. The analytical method used is descriptive analysis with the most data on the use of antiviral drugs and the average percentage for the period August 2021 at dr. Murjani-Sampit which opened 275 patients. The results showed that the most widely administered antivirals were favipiravir 200 mg in 249 patients (90.54%), remdesivir 200 mg in 17 patients (6.18%) and oseltamivir as adjuvant or additional therapy due to influenza in 9 patients (3.27%). The conclusion of this study is that the antivirals used include oseltamivir 75 mg 3.27%, favipiravir 200 mg 90.54%, and remdesivir 200 mg 6.18%.]]>
<![CDATA[EFEKTIVITAS ANTIBIOTIK PADA PASIEN PNEUMONIA COVID-19 : STUDI OBSERVASIONAL ]]>
<![CDATA[Farid Zulkarnain Nur Syah]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>;
<![CDATA[Rella Indah Karunia]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 2 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36387/jiis.v7i2.878
<![CDATA[COVID-19 has become a deadly pandemic worldwide. The use of empiric antibiotics in cases of COVID-19 pneumonia has the risk of triggering bacterial resistance. The purpose of the study was to analyze the use of antibiotics used in cases of COVID-19 pneumonia. The design of the study was an observational study conducted retrospectively from June 2021 to August 2021. The subjects of the study were patients with confirmed COVID-19 pneumonia, as diagnosed by the doctor based on the results of a chest CT scan and PCR. The total number of research subjects was 111. The antibiotics used were azithromycin (n = 42) and levofloxacin (n = 69). There was no significant difference between the initial clinical condition of hospital admission in subjects receiving azithromycin and subjects receiving levofloxacin (p=0.098) based on the WHO clinical progression scale score. There was a significant difference between azithromycin and levofloxacin for the length of therapy (p = 0.000) and length of hospitalization (p = 0.004). There was a significant difference (p = 0.006) in clinical conditions based on WHO clinical progression scale scores before and after using azithromycin. There was no significant difference (p = 0.114) in clinical conditions before and after using levofloxacin. There was no significant difference in mortality (p = 0.275) between the two types of antibiotics. Subject mortality was not affected by gender, advanced age (> 65 years), and comorbid disease. Azithromycin is more effective in improving the clinical condition of patients with COVID-19 pneumonia compared to levofloxacin.]]>
<![CDATA[EFEKTIVITAS ANTIVIRUS OSELTAMIVIR PADA SUBJEK COVID-19 DENGAN ATAU TANPA PENYAKIT PENYERTA DI PUSKESMAS ARUT SELATAN – PANGKALAN BUN ]]>
<![CDATA[Soufia Ardiani]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 2 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36387/jiis.v7i2.879
<![CDATA[South Arut occupies the highest position with 51.55% of the total COVID-19 cases in Kota Waringin Barat, Central Borneo. The purpose of the study was to determine patient characteristics and analyze the effectiveness of oseltamivir in COVID-19 patients. The research design was an observational study and data collected retrospectively. Inclusion criteria were COVID-19 subjects with or without comorbidities and outpatient treatment at the Arut Selatan, Pangkalan-Bun Health Center who were given Oseltamivir. Parameters of therapeutic effectiveness were measured by the WHO Clinical Progression Scale consisting of 5 levels of clinical condition of patients with a score range of 0 (uninfected) – 10 (died). Data analysis was descriptively grouped according to clinical progression scale scores. The results of the study of 107 subjects were mostly male (56.1%) and aged 26-45 years (34.6%). The clinical results of therapy were 0.9% of subjects recovered with negative swab results (score 0), 98.2% improved (score 1), and 0.9% died (score 10). There were no subjects who needed to be referred to the hospital, Self-quarantine of 8-15 days showed 96 (89.7%) subjects experienced clinical improvement, symptoms free, and swab results were negative. It could be concluded that oseltamivir was effective for mild Covid-19 subjects in South Arut, Pangkalan Bun, Kota Waringin, Central Borneo.]]>
<![CDATA[TERAPI FAVIPIRAVIR PADA SUBYEK COVID-19 DERAJAT SEDANG TANPA GANGGUAN LIVER DI RS PUSAT INFEKSI PROF DR SULIANTI SAROSO ]]>
<![CDATA[Hastutik Cairn Brisbane]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>;
<![CDATA[Rosamarlina Rosamarlina]]>;
<![CDATA[Memy Aviatin]]>;
<![CDATA[Adria Rusli]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 2 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36387/jiis.v7i2.880
<![CDATA[The outbreak of the corona virus which first contracted in December 2019 in Wuhan, China; Currently it has been designated by the World Health Organization (WHO) as a pandemic and is known as Corona Virus Infection Disease 2019 (Covid-19). This study aimed to describe the profile of favipiravir therapy in moderate COVID-19 inpatients without liver impairment at Prof. dr. Sulianti Saroso Infection Center Hospital. The design of this study was an observational study conducted retrospectively. All the patients in this research were received favipiravir loading dose of 1600 mg bid on the first day, and 600 mg bid starting on the day-2 of therapy. The results of the research were 81 moderate Covid-19 inpatients without history or recent liver impairment who were hospitalized in the period October 2020 - July 2021 dominating by female gender (56%). Mode of hospital admission were self-referral to Prof. dr. Sulianti Saroso Infection Center Hospital (83%), primary care (Puskesmas) referral (12%), and other hospital referral (5%). There were no comorbidity in 74,1% of the subjects. Among 25,9% subjects with comorbidity, most of the patients suffered from hypertension (29%); hypertension, and cardiovascular disease (17%). diabetes (12%); diabetes and hypertension (12%); Asthma (12). None of the subjects experienced increased in liver transaminases (ALT, AST), nor ALP and total bilirubin. Eighty-one patients were either cured (12%) with negative PCR test results or improved (88%) at the end of the therapy.]]>
<![CDATA[EFEKTIVITAS ANTIBIOTIK PADA PASIEN PNEUMONIA COVID-19 : STUDI OBSERVASIONAL ]]>
<![CDATA[Farid Zulkarnain Nur Syah]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>;
<![CDATA[Rella Indah Karunia]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 2 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36387/jiis.v7i2.878
<![CDATA[COVID-19 has become a deadly pandemic worldwide. The use of empiric antibiotics in cases of COVID-19 pneumonia has the risk of triggering bacterial resistance. The purpose of the study was to analyze the use of antibiotics used in cases of COVID-19 pneumonia. The design of the study was an observational study conducted retrospectively from June 2021 to August 2021. The subjects of the study were patients with confirmed COVID-19 pneumonia, as diagnosed by the doctor based on the results of a chest CT scan and PCR. The total number of research subjects was 111. The antibiotics used were azithromycin (n = 42) and levofloxacin (n = 69). There was no significant difference between the initial clinical condition of hospital admission in subjects receiving azithromycin and subjects receiving levofloxacin (p=0.098) based on the WHO clinical progression scale score. There was a significant difference between azithromycin and levofloxacin for the length of therapy (p = 0.000) and length of hospitalization (p = 0.004). There was a significant difference (p = 0.006) in clinical conditions based on WHO clinical progression scale scores before and after using azithromycin. There was no significant difference (p = 0.114) in clinical conditions before and after using levofloxacin. There was no significant difference in mortality (p = 0.275) between the two types of antibiotics. Subject mortality was not affected by gender, advanced age (> 65 years), and comorbid disease. Azithromycin is more effective in improving the clinical condition of patients with COVID-19 pneumonia compared to levofloxacin.]]>
<![CDATA[EFEKTIVITAS ANTIVIRUS OSELTAMIVIR PADA SUBJEK COVID-19 DENGAN ATAU TANPA PENYAKIT PENYERTA DI PUSKESMAS ARUT SELATAN – PANGKALAN BUN ]]>
<![CDATA[Soufia Ardiani]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 2 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36387/jiis.v7i2.879
<![CDATA[South Arut occupies the highest position with 51.55% of the total COVID-19 cases in Kota Waringin Barat, Central Borneo. The purpose of the study was to determine patient characteristics and analyze the effectiveness of oseltamivir in COVID-19 patients. The research design was an observational study and data collected retrospectively. Inclusion criteria were COVID-19 subjects with or without comorbidities and outpatient treatment at the Arut Selatan, Pangkalan-Bun Health Center who were given Oseltamivir. Parameters of therapeutic effectiveness were measured by the WHO Clinical Progression Scale consisting of 5 levels of clinical condition of patients with a score range of 0 (uninfected) – 10 (died). Data analysis was descriptively grouped according to clinical progression scale scores. The results of the study of 107 subjects were mostly male (56.1%) and aged 26-45 years (34.6%). The clinical results of therapy were 0.9% of subjects recovered with negative swab results (score 0), 98.2% improved (score 1), and 0.9% died (score 10). There were no subjects who needed to be referred to the hospital, Self-quarantine of 8-15 days showed 96 (89.7%) subjects experienced clinical improvement, symptoms free, and swab results were negative. It could be concluded that oseltamivir was effective for mild Covid-19 subjects in South Arut, Pangkalan Bun, Kota Waringin, Central Borneo.]]>
<![CDATA[TERAPI FAVIPIRAVIR PADA SUBYEK COVID-19 DERAJAT SEDANG TANPA GANGGUAN LIVER DI RS PUSAT INFEKSI PROF DR SULIANTI SAROSO ]]>
<![CDATA[Hastutik Cairn Brisbane]]>;
<![CDATA[Abdul Rahem]]>;
<![CDATA[Anita Purnamayanti]]>;
<![CDATA[Rosamarlina Rosamarlina]]>;
<![CDATA[Memy Aviatin]]>;
<![CDATA[Adria Rusli]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 7 No 2 (2022): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36387/jiis.v7i2.880
<![CDATA[The outbreak of the corona virus which first contracted in December 2019 in Wuhan, China; Currently it has been designated by the World Health Organization (WHO) as a pandemic and is known as Corona Virus Infection Disease 2019 (Covid-19). This study aimed to describe the profile of favipiravir therapy in moderate COVID-19 inpatients without liver impairment at Prof. dr. Sulianti Saroso Infection Center Hospital. The design of this study was an observational study conducted retrospectively. All the patients in this research were received favipiravir loading dose of 1600 mg bid on the first day, and 600 mg bid starting on the day-2 of therapy. The results of the research were 81 moderate Covid-19 inpatients without history or recent liver impairment who were hospitalized in the period October 2020 - July 2021 dominating by female gender (56%). Mode of hospital admission were self-referral to Prof. dr. Sulianti Saroso Infection Center Hospital (83%), primary care (Puskesmas) referral (12%), and other hospital referral (5%). There were no comorbidity in 74,1% of the subjects. Among 25,9% subjects with comorbidity, most of the patients suffered from hypertension (29%); hypertension, and cardiovascular disease (17%). diabetes (12%); diabetes and hypertension (12%); Asthma (12). None of the subjects experienced increased in liver transaminases (ALT, AST), nor ALP and total bilirubin. Eighty-one patients were either cured (12%) with negative PCR test results or improved (88%) at the end of the therapy.]]>
<![CDATA[PROFIL PENGETAHUAN DAN PERSPEKTIF HIPNOTERAPI DI KALANGAN MASYARAKAT WILAYAH SURABAYA ]]>
<![CDATA[Fauziyyah Syandria Afrisa]]>;
<![CDATA[Amara Damayanti]]>;
<![CDATA[Mutmainnah Mutmainnah]]>;
<![CDATA[Shabrina Insan Nabil]]>;
<![CDATA[Luthfia Andini Nathaneila]]>;
<![CDATA[Febri Zalfa’ Pratama]]>;
<![CDATA[Avif Muhammad Zaki Hidayat]]>;
<![CDATA[Reza Fahlevy Firmansyah Putra]]>;
<![CDATA[Alwiyah Alwiyah]]>;
<![CDATA[Abdul Rahem]]>
<![CDATA[ Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan Vol 8 No 1 (2023): JIIS ]]>
Publisher : <![CDATA[Sekolah Tinggi Ilmu Kesehatan ISFI Banjarmasin ]]>
Show Abstract
|
Download Original
|
Original Source
|
Check in Google Scholar
|
DOI: 10.36387/jiis.v8i1.1259
<![CDATA[Hypnotherapy is an alternative and complementary therapy or non-pharmacological therapy that uses hypnosis as a suggestion of the human unconscious. Many people are negative about hypnotherapy and do not know that it has many benefits. The purpose of this study is expected to increase knowledge and change people's perspectives on hypnotherapy treatment. This study is a cross sectional study with non-random sampling (accidental sampling) techniques with research instruments in the form of online questionnaires and spread leaflets. The study was 108 respondents, with 108 respondents meeting the inclusion criteria. The results of the knowledge study showed 38.0% with good knowledge, 46.3% of respondents with sufficient knowledge and 15.7% of respondents with low knowledge and results at perspective showed 18% of respondents were positive, and 82% were negative. Based on the results of the respondents' knowledge and perspective, there is a need for an introduction to hypnotherapy treatment to prevent misperception among the people of Surabaya.]]>
